Allarity Therapeutics, Inc. (ALLR)
(Real Time Quote from BATS)
$0.16 USD
-0.01 (-4.76%)
Updated Jul 22, 2024 09:34 AM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALLR 0.16 -0.01(-4.76%)
Will ALLR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALLR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLR
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
ALLR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ALLR
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
Allarity provides 2024 corporate update
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Allarity Therapeutics Secures Critical Nasdaq Hearing Opportunity
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance